TNF Pharmaceuticals Files 8-K on Shareholder Nominations
Ticker: QCLS · Form: 8-K · Filed: Sep 23, 2024 · CIK: 1321834
| Field | Detail |
|---|---|
| Company | Tnf Pharmaceuticals, Inc. (QCLS) |
| Form Type | 8-K |
| Filed Date | Sep 23, 2024 |
| Risk Level | medium |
| Pages | 3 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: shareholder-nomination, corporate-governance, 8-k
TL;DR
TNF Pharma filed an 8-K about shareholder nominations for the board. Get ready for potential shake-ups.
AI Summary
On September 20, 2024, TNF Pharmaceuticals, Inc. filed an 8-K report detailing shareholder nominations for its upcoming annual meeting. The company, formerly known as MyMD Pharmaceuticals, Inc., is incorporated in Delaware and headquartered in Baltimore, MD.
Why It Matters
This filing indicates active shareholder engagement and potential changes in board composition, which could influence the company's strategic direction.
Risk Assessment
Risk Level: medium — Shareholder nominations can signal dissatisfaction or a push for strategic changes, introducing uncertainty.
Key Players & Entities
- TNF Pharmaceuticals, Inc. (company) — Registrant
- MyMD Pharmaceuticals, Inc. (company) — Former company name
- Akers Biosciences, Inc. (company) — Former company name
- September 20, 2024 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- Baltimore, MD (location) — Business address
FAQ
What is the primary purpose of this 8-K filing?
The primary purpose of this 8-K filing is to report shareholder nominations for the company's upcoming annual meeting.
What was TNF Pharmaceuticals, Inc. formerly known as?
TNF Pharmaceuticals, Inc. was formerly known as MyMD Pharmaceuticals, Inc.
When was the earliest event reported in this filing?
The earliest event reported in this filing was on September 20, 2024.
In which state is TNF Pharmaceuticals, Inc. incorporated?
TNF Pharmaceuticals, Inc. is incorporated in Delaware.
What is the business address of TNF Pharmaceuticals, Inc.?
The business address of TNF Pharmaceuticals, Inc. is 855 N. Wolfe Street, Suite 623, Baltimore, MD.
Filing Stats: 817 words · 3 min read · ~3 pages · Grade level 14 · Accepted 2024-09-23 16:31:17
Key Financial Figures
- $0.001 — ch registered Common stock, par value $0.001 per share TNFA The Nasdaq Capital M
Filing Documents
- form8-k.htm (8-K) — 37KB
- 0001493152-24-037819.txt ( ) — 209KB
- tnfa-20240920.xsd (EX-101.SCH) — 3KB
- tnfa-20240920_lab.xml (EX-101.LAB) — 33KB
- tnfa-20240920_pre.xml (EX-101.PRE) — 24KB
- form8-k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. TNF PHARMACEUTICALS, INC. Date: September 23, 2024 By: /s/ Joshua Silverman Name: Joshua Silverman Title: Director